Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Membership Benefits
ACS
COVID-19

Indication Expands for COVID-19 Vaccine and Boosters for Young Children

May 24, 2022

CDC Expands Eligibility and Strengthens Booster Recommendations

Last week, the US Centers for Disease Control and Prevention released a statement that described updated recommendations for use of booster doses of the Pfizer-BioNTech COVID-19 vaccine. The organization now recommends that all individuals 5 years of age and older receive a booster dose 5 months after their initial two-part vaccine series.

Additionally, the CDC strengthened its recommendations that individuals 12 and older who are immunocompromised and all adults older than 50 should receive a second booster dose at least 4 months after their first.

Pfizer-Biotech Sees Progress in Vaccines for Young Children

Pfizer-BioNTech recently made progress toward getting respective vaccines approved under Emergency Use Authorization for children 5 years old and younger. 

According to Pfizer-BioNTech, their three-micro dose vaccine series for young children has generated a strong immune response and has been well-tolerated in a clinical trial comprising more than 1,600 children. The test dose showed children had a similar immune response as individuals in the vaccinated 16- to 25-year-old age group, with a vaccine effectiveness of more than 80%, though additional symptomatic COVID-19 cases in vaccinated children still need to be analyzed to better calculate efficacy.